Resonance Specialties shareholders approved a final dividend of ₹1 per share and authorized related party transactions worth up to ₹40 crore during its 37th Annual General Meeting held on August 4, 2026. While the dividend and auditor re-appointment resolutions passed with near-unanimous support, the related party transaction resolution encountered measurable dissent from public investors, marking a divergence in shareholder sentiment.

The virtual meeting, presided over by Chairman Raj Kamal Prasad Verma, saw all six proposed resolutions passed. The Board of Directors proposed the dividend at 10% on the face value of ₹10 per equity share. Voting was conducted electronically between July 31, 2026, and August 3, 2026, with July 28, 2026, as the cut-off date. M/s Alok Khairwar & Associates served as the scrutinizer under Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Breakdown by Resolution

Promoter group holdings of 6,262,201 shares voted in favor of all resolutions except the related party transaction, where they abstained. Public institutional holders did not vote on any resolution. The key differentiator was the "Public-Others" category, which held 5,106,148 shares but polled only 16,170 votes (0.3167% participation).

Governance and Compliance

The meeting adhered to strict regulatory standards. Representatives from Statutory Auditors, Secretarial Auditors, and the Scrutinizer were present via video conference. Chairman Raj Kamal Prasad Verma confirmed quorum presence throughout. He noted no qualifications or adverse remarks in the Independent Auditors Report or Secretarial Audit Report for the period ended March 31, 2026.

The Whole-time Director addressed member queries before the e-voting module remained open for an additional 15 minutes. Results were declared following the scrutinizer’s report and posted on the company’s website and registered office in Mumbai.

What the Numbers Show

The stark contrast in voting patterns reveals specific shareholder concerns. While governance items (auditors, director re-appointment) and capital return (dividend) enjoyed universal support, the related party transaction cap of ₹40 crore with Kaygee Laboratories Private Limited faced 745 votes against from the public-investor segment. This 4.6% opposition rate is significant given the low overall participation (0.31%) of retail investors. It suggests that while promoters are fully aligned with management, a subset of public shareholders remains cautious about the scale or terms of ongoing commercial ties with Kaygee Laboratories, despite the annual oversight mechanism.

Resonance Specialties Limited reported a sharp 252% year-on-year surge in net profit to ₹574.42 lakhs for the quarter ended June 30, 2026, driven primarily by a doubling of international revenues. The Board of Directors, meeting on August 4, 2026, approved the unaudited financial results and simultaneously greenlit the acquisition of a strategic manufacturing facility in Madhya Pradesh for ₹29.98 crores. This dual announcement signals both strong operational performance and aggressive capacity expansion through vertical integration.

Financial Performance Highlights

Revenue from operations rose to ₹3,258.41 lakhs in Q1FY27, up from ₹2,127.42 lakhs in the corresponding period of FY26. Total income stood at ₹3,312.19 lakhs, including other income of ₹53.78 lakhs. Profit before tax jumped to ₹764.93 lakhs from ₹237.24 lakhs year-ago. The company’s basic and diluted earnings per share (EPS) were ₹4.98 each, compared to ₹1.41 in Q1FY26.

Expense Management and Margins

Total expenses increased to ₹2,547.26 lakhs from ₹1,912.89 lakhs, reflecting higher input costs associated with increased production volumes. Key expense components included cost of materials consumed at ₹1,360.36 lakhs and conversion charges at ₹332.13 lakhs. Employee benefits expense rose to ₹161.93 lakhs from ₹141.96 lakhs. Finance costs remained negligible at ₹1.27 lakhs. The expansion in revenue outpaced the rise in expenses, leading to improved operating leverage.

Export-Led Growth

The primary driver of the financial performance was robust international demand. Revenue from outside India more than doubled to ₹2,326.08 lakhs from ₹1,065.49 lakhs in Q1FY26, accounting for approximately 71% of total revenue. Domestic revenue from India declined slightly to ₹932.33 lakhs from ₹1,061.93 lakhs. This shift underscores the company’s growing reliance on global markets for specialty chemicals and APIs.

Acquisition of Mandideep Facility

In a significant strategic move, Resonance Specialties approved the purchase of a manufacturing facility at Plot No. 6, New Industrial Area-II, Mandideep, Madhya Pradesh, from Kaygee Laboratories Private Limited (KLPL), a promoter group entity. The transaction, valued at ₹29.98 crores on a slump sale basis, includes leasehold land of 22,304 sq. mtrs., industrial buildings of 5,227 sq. mtrs., plant machinery, licenses, and employees.

The facility, originally set up in 1990, has been supplying chemical intermediates and APIs to Resonance Specialties on a job work basis. It was recently inspected and approved by WHO, Geneva. The acquisition aims to secure uninterrupted production, enhance operational control, and eliminate outsourcing costs. Shareholder approval is required for the transaction, which is expected to be completed by November 30, 2026. The deal is structured as an arm’s length related party transaction based on an independent valuer’s certificate.

Auditor’s Review and Compliance

The unaudited financial results were reviewed by Kailash Chand Jain & Co., Chartered Accountants, who issued a limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The auditors noted no material misstatements. The results were prepared in accordance with Ind AS-34 and reviewed by the audit committee before Board approval. As of June 30, 2026, the company has no subsidiaries, associates, or joint ventures.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE486D01017/1e4cca1b-2470-47b7-87cc-73573d40d388.pdf